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Abstract
Objectives: Patients with minimal-change chronic pancreatitis (MCCP) are traditionally managed medi-
cally with poor results. This study was conducted to review outcomes following total pancreatectomy with
islet cell autotransplantation (TP/IAT) as the initial surgical procedure in the treatment of MCCP.
Methods: All patients submitted to TP/IAT for MCCP were identified for inclusion in a single-centre
observational study. A retrospective chart review was performed to identify pertinent preoperative,
perioperative and postoperative data.
Results: A total of 84 patients with a mean age of 36.5 years (range: 15–60 years) underwent TP/IAT
as the initial treatment for MCCP. The most common aetiology of chronic pancreatitis in this cohort
was idiopathic (69.0%, n = 58), followed by aetiologies associated with genetic mutations (16.7%, n = 14),
pancreatic divisum (9.5%, n = 8), and alcohol (4.8%, n = 4). The most common genetic mutations
pertained to CFTR (n = 9), SPINK1 (n = 3) and PRSS1 (n = 2). Mean ± standard error of the mean
preoperative narcotic requirements were 129.3 ± 18.7 morphine-equivalent milligrams (MEQ)/day. Overall,
58.3% (n = 49) of patients achieved narcotic independence and the remaining patients required 59.4 ±
10.6 MEQ/day (P < 0.05). Postoperative insulin independence was achieved by 36.9% (n = 31) of patients.
The Short-Form 36-Item Health Survey administered postoperatively demonstrated improvement in all
tested quality of life subscales.
Conclusions: The present report represents one of the largest series demonstrating the benefits of
TP/IAT in the subset of patients with MCCP.
Received 20 May 2014; accepted 18 August 2014
Correspondence
Syed A. Ahmad, Division of Surgical Oncology, Department of Surgery, University of Cincinnati School of
Medicine, 234 Goodman Street, ML 0772, Cincinnati, OH 45219, USA. Tel: + 1 513 584 8900. Fax: +
1 513 584 0459. E-mail: ahmadsy@uc.edu
Introduction
Minimal-change chronic pancreatitis (MCCP) is characterized by
chronic inflammatory destruction of the gland with subsequent
exocrine/endocrine dysfunction and persistent abdominal pain
without main duct dilation.1 In a subset of these patients, findings
are so subtle that classical imaging modalities often do not
detect the findings of chronic pancreatitis (CP). These patients
usually present with debilitating abdominal pain or recurrent
acute pancreatitis. When present, the disease usually involves the
entire gland. Traditional management strategies have historically
focused onmedical therapy for the control of symptoms. Exocrine
dysfunction has been abated through the administration of
replacement enzymes. Endocrine dysfunction and the resulting
diabetes have been managed with oral hypoglycaemic medica-
tions and/or exogenous insulin administration. Attempts at
pain management are made by escalating analgesic and narcotic
regimens.2
It was commonly accepted that CP would progress to the point
of organ failure or burnout, at which point the patient’s abdomi-
nal pain would subside.3 Therefore, medical management was
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considered the standard of care and narcotic medications repre-
sented an ideal bridging therapy until organ burnout occurred.
Additional studies have since questioned this burnout phenom-
enon and demonstrated that abdominal pain persisted in the
majority of patients with CP over a 10-year follow-up period.4 In
MCCP, not only does pain persist, but almost 80% of patients
experience worsening functional status despite optimal medical
management.5 Given the inadequacies of medical management
in MCCP, surgical intervention has been advocated for patients
with refractory disease. Lateral pancreaticojejunostomy with or
without limited gland resection has been widely accepted for the
treatment of large duct CP,6–9 but it does not address the under-
lying pathophysiology in MCCP.10 The development of surgical
interventions for the treatment of MCCP has focused on varying
degrees of gland resection. Classical and pylorus-preserving
pancreaticoduodenectomy (PD) have been shown to provide
benefit in head-dominant disease, but the remnant gland provides
a source of persistent disease.1,11 Izbicki et al. and Yekebas et al.
reported on the benefits of longitudinal excision of the ventral
pancreas for small duct disease and demonstrated pain reduction
in the majority of patients.12,13 Near-total or total pancreatectomy
(TP) was largely reserved for the worst cases because of its
associated morbidity, but its use in the treatment of CP has
been rejuvenated with advances in islet cell autotransplantation
(IAT).14–16
At the study institution, practitioners have advocated for
TP/IAT as the initial procedure for patients with MCCP. This
paper reports on outcomes in a series of patients submitted to
TP/IAT as the initial surgical intervention for the treatment of
MCCP with an emphasis on islet yields, postoperative insulin and
narcotic requirements, and standardized quality of life (QoL)
assessments.
Materials and methods
Patient selection
Patients referred to the University of Cincinnati Pancreatic
Disease Center were submitted to a thorough multidisciplinary
team evaluation conducted by practitioners in gastroenterology,
endocrinology, radiology and pancreatic surgery.Minimal-change
CP was diagnosed according to the results of imaging and
functional testing, and patient symptomatology that was consist-
ent with CP but in the absence of pancreatic duct dilation.
Imaging modalities included computed tomography (CT),
endoscopic ultrasound (EUS) and endoscopic retrograde
cholangiopancreatography (ERCP). Functional testing included
the measurement of fecal fat and elastase levels in conjunction
with pancreatic bicarbonate levels. In most patients, diagnosis was
based on clinical symptoms and confirmed with EUS, ERCP and
CT findings. Confirmation with EUS required the presence
of four or more of the nine conventional criteria: parenchymal
findings included hyperechoic foci, hyperechoic stranding,
hyperechoic lobularity and cysts, and ductal findings included
irregular duct contour, hyperechoic ductal margin, visible side
branches, and ductal calculi.17 If a patient had fewer than four
(Rosemont or conventional) findings but a concomitant major
finding (stones or honeycomb lobularity), that patient was diag-
nosed with MCCP. The confirmation of a diagnosis by ERCP was
based on the Cambridge classification.18 Patients with Cambridge
II and III disease were designated as having MCCP. Patients with
debilitating pain and/or a disturbed QoL despite maximal medical
and endoscopic management were considered as surgical candi-
dates. At the study institution, TP/IAT was offered to patients with
MCCP as the initial surgical intervention, but was only considered
in patients with type 2 diabetes mellitus if they were insulin-
independent or required <0.5 units of insulin per kilogram body
weight per day.
Operative procedure and islet cell transplantation
Total pancreatectomy was performed in all patients and included
splenectomy and resection of the duodenum and distal common
bile duct. The body and tail of the pancreas were mobilized first
and the pancreatic blood supply was preserved as long as pos-
sible to minimize islet cell ischaemia. The distal pancreas was
divided at the level of the superior mesenteric vein and infused
with enzymatic solution through the pancreatic duct. Islet cell
isolation was performed by enzymatic degradation of the pan-
creatic tissue as previously described.19,20 Cell viability was con-
firmed with acridine orange and propidium iodine staining and
alamar blue staining. Islet cells were suspended in 5% albumin
solution containing heparin at 70 units per kilogram of body
weight and transplanted via portal vein infusion. Roux-en-Y sur-
gical reconstruction consisted of choledochojejunostomy and
gastrojejunostomy.
Postoperative care
All patients were monitored in the surgical intensive care unit
following TP/IAT for insulin infusion and strict blood glucose
control (serum levels of <120 mg/dl). Patients were converted to a
basal bolus insulin regimen starting on postoperative day 3. Strict
glycaemic control was maintained throughout the hospitalization
and all patients were discharged to home with an insulin regimen.
All patients were counselled on the management of diabetes prior
to hospital discharge. Insulin regimens were adjusted and weaned
based on a review of patient blood glucose journals and haemo-
globin A1c levels by the patient’s endocrinologist.
Data collection and statistical analysis
This study was approved by the University of Cincinnati Institu-
tional Review Board and informed consent was obtained from
all study participants. The University of Cincinnati Pancreatic
Disease Center patient database was reviewed to identify all
patients submitted to TP/IAT for MCCP between 2002 and 2012.
A retrospective chart review identified pertinent preoperative,
intraoperative and postoperative details. The overall mean ±
standard error of the mean (SEM) follow-up time for the patient
cohort was 32.0 ± 3.4 months after TP/IAT. All medication
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requirements were determined from prescriptions listed in the
patients’ medical records; subjective reports of narcotic use were
not included. Narcotic requirements are reported as morphine-
equivalent milligrams per day (MEQ/day) and were calculated
using narcotic conversion software [Narcotic Converter;
GlobalRPH, Inc. (http://www.globalrph.com/narcotic_converter
.htm)]. Only scheduled narcotic medications were reported.
Quality of life after TP/IAT was assessed in a cross-sectional
manner with the Short-Form 36-Item Health Survey (SF-36) and
standardized scoring module.21,22
Results
Patients
Eighty-four patients underwent TP/IAT as the initial surgical
intervention for the treatment of MCCP at the University of Cin-
cinnati between January 2002 and June 2012. Patient demograph-
ics are presented in Table 1. The mean patient age was 36.5 years
(range: 15–60 years) and the majority were female (n = 56,
66.7%). Idiopathic MCCP was the most common aetiology (n =
58, 69.0%), followed by an identifiable predisposing genetic muta-
tion (n = 14, 16.7%), pancreatic divisum (n = 8, 9.5%), and
alcohol-induced CP (n = 4, 4.8%). In patients with identifiable
genetic mutations, CFTR gene mutations predominated (n = 9,
64.3%), followed by SPINK1 (n = 3, 21.4%) and PRSS1 (n = 2,
14.3%) mutations. Specific mutations are listed in Table 1. Nine
(10.7%) of the patients submitted to TP/IAT for MCCP had been
diagnosed with diabetes prior to the operation. Three of these
patients were insulin-dependent (mean ± SEM insulin require-
ment: 9.4 ± 5.6 U/day) and the remaining six were taking oral
hypoglycaemic medications only.
Perioperative details
Islet cell autotransplantation was successfully performed in all
patients. The mean ± SEM islet yield for the entire cohort was
440 759 ± 29 024 islet equivalents (IEQ), which represented a
mean ± SEM of 6342 ± 439 IEQ per kg body weight. The mean ±
SEM operative time was 556.0 ± 10.9 min, which included tissue
harvesting, islet cell isolation and autotransplantation. Mean ±
SEM blood loss was 577 ± 64 ml and 24 (28.6%) patients required
blood transfusion. There were no perioperative deaths. The mean
± SEM length of hospital stay was 15.0 ± 0.9 days (Table 2).
Postoperative haemorrhage requiring reoperation occurred in
five (6.0%) patients. Portal venous thrombosis occurred in two
patients; one patient required anticoagulation and the other
patient required mechanical and chemical thrombolysis. The
overall 30-day readmission rate was 29.8% (n = 25). The most
common reasons for readmission were infectious aetiologies and
abdominal pain; however, two patients were readmitted for
glycaemic control issues.
Insulin requirements
After TP/IAT, all patients were discharged from the hospital with
an insulin regimen in place. The mean ± SEM insulin requirement
was 17.1 ± 1.7 U/day (Table 3). At the most recent follow-up
appointment [median follow-up: 17 months, interquartile range
(IQR): 9.5–27.4 months], the majority of patients (52.4%, n = 44)
were found to have achieved stable glycaemic control requiring
little to no insulin (0–10 U/day). A total of 36.9% (n = 31) of
patients were insulin-independent at the most recent follow-up.
Two patients were readmitted within 30 days following TP/IAT
for glycaemic control issues which required additional diabetes
education and insulin regimen adjustment. Two patients experi-
enced a period of labile glycaemic control after TP/IAT that
required frequent glucose measurements, multiple insulin injec-
tions throughout the day, and frequent regimen adjustments,
but were successfully transitioned to regimens that achieved
stable glycaemic control. The remaining patients achieved stable
glycaemic control with a mean ± SEM insulin requirement of 14.5
± 1.8 U/day.
Table 1 Demographic data for 84 patients with minimal-change
chronic pancreatitis treated with total pancreatectomy with islet cell
autotransplantation
Patient characteristic Value
Age, years, mean ± SEM (range) 36.5 ± 11.8 (15–60)
Weight, kg, mean ± SEM (range) 72.1 ± 18.0 (42–116)
BMI, kg/m2, mean ± SEM (range) 24.7 ± 6.7 (14–49)
Sex, n (%)
Male 28 (33.3%)
Female 56 (66.7%)
Diabetic, n (%) 9 (10.7%)
Aetiology, n (%)
Idiopathic 58 (69.0%)
Genetic 14 (16.7%)
CFTR 9
ΔF508 3
ΔF508 + M470V 1
ΔF508 + R117H 1
R117H 1
P750L 1
R31C 1
5T variant 1
SPINK1 3
N34S 3
PRSS1 2
R122H 1
N29I 1
Divisum 8 (9.5%)
Alcohol 4 (4.8%)
BMI, body mass index; CFTR, cystic fibrosis transmembrane conduct-
ance regulator; PRSS1, cationic trypsinogen; SEM, standard error of the
mean; SPINK1, serine protease inhibitor, Kazal type 1.
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Of the nine patients in the cohort who underwent TP/IAT
subsequent to a previous diagnosis of diabetes mellitus, only one
was insulin-independent at the most recent follow-up. Seven of
these patients achieved stable glycaemic control with a mean ±
SEM daily insulin requirement of 26.9 ± 5.7 U. The remaining
patient required 30 U/day of insulin and died 1 year after TP/IAT
secondary to acute ethanol intoxication and diabetic ketoacidosis.
Narcotic requirements
Mean preoperative narcotic requirements were 156.8 MEQ/day
(Table 3). Narcotic requirements decreased to 52.9 MEQ/day
(P = 0.006) by 6 months after TP/IAT. Narcotic requirements at
the most recent follow-up (median: 17 months; IQR: 9.5–27.4
months) were 64.3 MEQ/day and 58.3% (n = 49) of patients were
narcotic-independent. Only 7.1% (n = 6) of patients continued to
require high-dose (>200 MEQ/day) narcotic medications after
TP/IAT.
Quality of life assessment
Patient QoL was assessed using the SF-36. Cross-sectional analysis
was performed at a median of 76 months (IQR: 20–83 months)
postoperatively. Mean scores for each subscale of the survey are
presented in Table 4. Scores on the survey are given on a scale of
0–100, where 100 represents the best functional level. All mean
subscale scores were increased from previously published baseline
scores for patients with CP.15 Thirty (88.2%) of the patients sur-
veyed reported an overall improvement in their health in com-
parison with their status 1 year earlier, one patient reported no
change and three reported worse overall health. Improvements in
the QoL subscales after TP/IAT persisted well beyond the immedi-
ate postoperative period (Table 4). Quality of life surveys admin-
istered to patients over 5 years after TP/IAT again demonstrated
improvements on all subscales from previously published baseline
values and showed increases similar to those seen in patients
immediately following TP/IAT (0–5 years).
Discussion
The diagnosis and management of CP have continued to evolve in
line with enhanced understanding of the pathophysiology of the
disease and advances in procedural capabilities. The biggest con-
troversy relating to MCCP involves establishing the diagnosis of
MCCP and clarifying whether this represents an early step in the
progression of CP or its own unique disease subset.1,2,23 Currently,
there is no consensus on the definition and diagnosis of MCCP.
All patients referred to the University of Cincinnati Pancreatic
Disease Center undergo a thorough multidisciplinary evaluation
carried out by a team that includes specialists in gastroenterology,
Table 2 Perioperative findings in 84 patients with minimal-change
chronic pancreatitis treated with total pancreatectomy with islet cell
autotransplantation
Operative characteristic Value
Operative time, min,
mean ± SEM (range)
556.0 ± 10.9 (325–916)
Estimated blood loss, ml,
mean ± SEM (range)
577.1 ± 64.2 (75–3100)
Pancreas weight, g,
mean ± SEM (range)
69.5 ± 4.3 (21.3–188.4)
Total IEQ, mean ± SEM (range) 440 759 ± 29 024 (8450–1 057 550)
IEQ per kg body weight,
mean ± SEM (range)
6342 ± 439 (138–18 700)
Length of stay, days,
mean ± SEM (range)
15 ± 0.9 (4–50)
Major complications, n (%)
Postoperative haemorrhage 5 (6.0%)
Portal vein thrombosis 2 (2.4%)
ARDS 1 (1.2%)
Intra-abdominal abscess 8 (9.5%)
30-day readmission, n (%) 25 (29.8%)
Infectious 10
Abdominal pain 7
Dehydration 5
Glycaemic control 2
Pulmonary embolus 1
ARDS, acute respiratory distress syndrome; IEQ, islet cell equivalent;
SEM, standard error of the mean.
Table 3 Insulin and narcotic requirements in 84 patients with
minimal-change chronic pancreatitis treated with total pancreatec-
tomy with islet cell autotransplantation
Requirement Value
Insulin requirements, U/day, mean ± SEM
Preoperative 1.0 ± 0.7
At discharge from hospital 17.1 ± 1.7
At 6 months 13.6 ± 2.3
Most recent follow-upa 14.5 ± 1.8
Independent, n (%) 31 (36.9%)
0–10 U/day, n (%) 13 (15.5%)
10–20 U/day, n (%) 11 (13.1%)
>20 U/day, n (%) 27 (32.1%)
Narcotic requirements, MEQ/day, mean ± SEM
Preoperative 161.5 ± 20.9
At discharge from hospital 130.6 ± 12.0
At 6 months 52.9 ± 11.2
Most recent follow-upa 59.4 ± 10.6
Independent, n (%) 49 (58.3%)
<50 MEQ/day, n (%) 10 (11.9%)
50–200 MEQ/day, n (%) 17 (20.2%)
>200 MEQ/day, n (%) 6 (7.1%)
aMedian most recent follow-up was 17.1 months (interquartile range:
9.5–27.4 months).
MEQ/day, morphine-equivalent milligrams of narcotics per day; SEM,
standard error of the mean; U/day, units of scheduled insulin per day.
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endocrinology, radiology, pain management and pancreatic
surgery. At this institution, the diagnosis of MCCP is based on
clinical presentation and confirmed with image findings consist-
ent with CP in the absence of pancreatic duct dilation. The
patients diagnosed with MCCP in the present cohort were not
representative of the traditional CP cohort, which is largely male
and in which alcohol-induced pancreatitis predominates.2,3 In
stark contrast, the present report refers to a cohort that was pre-
dominantly female and had either genetic mutation-associated or
idiopathic MCCP. These observations support the diagnosis of
MCCP as a separate, unique disease subset.
Establishing the diagnosis of MCCP clearly remains one of the
important fundamentals in managing this difficult patient popu-
lation. Endoscopic ultrasound has emerged as the predominant
imaging modality in this patient group. At the study institution,
the diagnosis of MCCP is confirmed by the presence of four or
more of the nine conventional criteria or, in patients with fewer
than four findings, at least one major finding. Using a cut-off of
four criteria has been shown to provide for high sensitivity, speci-
ficity and accuracy in the diagnosis of non-calcific CP.24 Deter-
mining the ideal cut-off for the number of criteria needed to
confirm the diagnosis of CP remains controversial. Recent reports
have advocated for higher criteria thresholds in establishing the
diagnosis of CP.25 Based on the present authors’ clinical experi-
ence, increasing this threshold would lower the specificity of the
test and result in the inappropriate treatment of patients who
otherwise might benefit from surgical intervention.
Regardless of the classification, these patients present with
debilitating pain that is refractory to traditional medical and
endoscopic management.1,5,23 Several institutions, including
the University of Cincinnati, have developed treatment algorithms
specifically tailored towards the management of patients
with MCCP. The decision model in this centre’s present treat-
ment algorithm focuses on disease morphology in order to
determine the ideal surgical intervention. The benefits of
pancreaticoduodenectomy and duodenum-preserving pancreatic
head resection have been well documented in the treatment of
MCCP with isolated head disease.1,2,26 Izbicki et al. and Yekebas
et al. reported on the benefits of a novel procedure in patients with
small duct disease using a longitudinal V-shaped excision of the
ventral pancreas.12,13 Despite the initial pain relief afforded by
these procedures, there remains a risk for recurrent pancreatitis in
the remnant gland.11 Total pancreatectomy has traditionally been
reserved for patients for whom no other options remain.However,
with advances in IAT, TP has been increasingly performed for
CP.15,16,20,27 The present authors believe that the best way of achiev-
ing longterm pain relief and improved QoL in MCCP involves
complete gland excision. Additionally, early intervention ensures
the adequate preservation of β cell mass before progressive glan-
dular destruction ensues and precludes a patient from IAT. Based
on these established results, the present group has focused its
surgical decision making on gland anatomy and disease morphol-
ogy. Patients with findings of a dilated pancreatic duct or isolated
focal disease are selected to undergo traditional ductal drainage
procedures and/or limited pancreatic gland resection. However,
in patients with findings of MCCP which are not amenable to
traditional procedures, the present authors have advocated for
TP/IAT as the initial surgical treatment for MCCP that is refrac-
tory to medical therapy. The current study represents the first to
specifically examine outcomes of TP/IAT as the initial surgical
procedure for MCCP. The current series demonstrates the hall-
marks of success after TP/IAT, which include longterm pain relief,
stable glycaemic control and overall improved QoL.
Chronic pain and narcotic dependence lead to lower levels of
function and decreased QoL in these patients. In the present
cohort, pain relief was achieved after TP/IAT with clear reductions
Table 4 Quality of life scores in patients with minimal-change chronic pancreatitis treated with total pancreatectomy with islet cell
autotransplantation
SF-36 category Overall 0–5 years >5 years P-valuea
(n = 34) (n = 16) (n = 18)
Physical health subscores
Physical functioning 76.2 ± 3.7 71.3 ± 5.6 80.6 ± 4.6 0.22
Role, physical limitations 37.5 ± 7.1 31.3 ± 10.2 43.1 ± 9.8 0.43
Bodily pain 51.5 ± 4.4 48.9 ± 6.8 53.8 ± 5.7 0.59
General health 44.6 ± 3.7 47.3 ± 5.2 42.2 ± 5.2 0.51
Vitality 52.1 ± 3.2 51.3 ± 5.2 52.8 ± 3.9 0.82
Mental health subscores
Social functioning 71.7 ± 4.5 70.3 ± 6.8 72.9 ± 5.8 0.78
Role, emotional limitations 62.7 ± 7.0 54.2 ± 10.6 70.4 ± 9.0 0.26
Mental health 74.4 ± 3.3 73.8 ± 4.7 74.9 ± 4.6 0.87
Improved health from 1 year previously, % 88.2% 87.5% 88.9%
aComparison of scores for 0–5 years and >5 years.
SF-36, Short-Form 36-Item Health Survey.
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in narcotic requirements. A total of 58.3% (n = 49) of patients in
the present series were narcotic-independent after the operation,
which is consistent with rates in previously published reports,15
and the remainder of patients showed significant reductions in
narcotic requirements. The SF-36 questionnaire was used to assess
the effects of CP, especially of chronic pain, on a patient’s lifestyle.
A cross-sectional analysis was performed after TP/IAT, in which
40.5% of patients were included. Outcomes on all of the subscales
tested were found to have improved in comparison with previ-
ously established baseline scores15 and 88.2% of respondents
reported an overall improvement in their health. The lack of
preoperative assessment is a clear limitation of this study, but the
use of validated questionnaires allows for the demonstration of
consistency between the improvements seen in the present cohort
and those in previously published reports.15 Additionally, these
improvements persisted well beyond the immediate postoperative
period, a finding that demonstrates evidence of the durability of
the results seen after TP/IAT.
Stable glycaemic control achieved with minimal insulin
requirements is the ultimate goal of IAT. This has a significant
impact on QoL after TP/IAT, as well as a profound impact on the
patient’s overall health.15 In addition to the retention of insulin-
producing β cells, islet cell transplantation also provides a source
of counter-regulatory hormones, including glucagon, to reduce
the incidence of ‘brittle’ diabetes and hypoglycaemic unrespon-
siveness.Although insulin independence is not the primary goal of
this operation, 36.9% of patients in the present series were
insulin-independent after TP/IAT. Additionally, 28.6% of patients
achieved stable glycaemic control with minimal (<20 U/day)
insulin requirements. High islet yields are likely to have con-
tributed to the high incidence of insulin independence and
low insulin requirements.28 The present mean islet yield of
6342 IEQ/kg body weight was higher than those in previously
published series,15,16,29 but not unexpected in this cohort, which
was naïve to previous pancreatic surgery. Early education on dia-
betes and longterm multidisciplinary follow-up are also critical to
the maintenance of successful glycaemic control after TP/IAT.
In summary, this study reports the outcomes of TP/IAT as the
initial surgical procedure in a large cohort of patients with MCCP.
In this patient population, establishing the correct diagnosis and
classification is imperative for surgical planning. A multidiscipli-
nary team approach remains the standard for the successful diag-
nosis and management of patients with CP. The treatment of
refractory MCCP with TP/IAT facilitates decreased narcotic
requirements, stable glycaemic control, and improved QoL, which
for many patients results in a return to their daily lives. This series
is the first to document the longterm (>5 years post-TP/IAT)
benefits of TP/IAT as the initial surgical intervention for MCCP.
Future studies are necessary to validate the subset of patients who
will benefit from TP/IAT based on radiographic definitions and
should further ascertain the best timing of the intervention in
order to maximize the achievement of pain relief and glycaemic
control.
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